Wealthfront Advisers LLC Cuts Stock Position in Abbott Laboratories $ABT

Key Points

• Wealthfront Advisers reduced its Abbott Laboratories position by 25.2% in the second quarter, selling 29,787 shares and retaining 88,206 shares valued at approximately $8.0 million. Institutional investors collectively own 75.18% of Abbott’s stock.
• Abbott exceeded quarterly expectations with $1.31 in adjusted EPS and $12.59 billion in revenue, while revenue rose 13% year over year. The company issued 2026 earnings guidance of $5.45–$5.60 per share and pays an annualized dividend of $2.52 per share, yielding about 2.2%.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and a $119.50 price target. Recent FDA and European approvals for Abbott’s Libre Duo glucose-ketone monitor and Amulet 360 heart device could support future growth, although the stock’s elevated valuation remains a risk.

Wealthfront Advisers LLC decreased its position in Abbott Laboratories (NYSE:ABT - Free Report) by 25.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 88,206 shares of the healthcare product maker's stock after selling 29,787 shares during the quarter. Wealthfront Advisers LLC's holdings in Abbott Laboratories were worth $8,004,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently made changes to their positions in the business. Foster & Motley Inc. raised its position in Abbott Laboratories by 11.6% in the 2nd quarter. Foster & Motley Inc. now owns 3,704 shares of the healthcare product maker's stock worth $336,000 after purchasing an additional 386 shares during the period. Cypress Asset Management Inc. TX increased its holdings in shares of Abbott Laboratories by 5.1% in the second quarter. Cypress Asset Management Inc. TX now owns 27,536 shares of the healthcare product maker's stock worth $2,499,000 after buying an additional 1,340 shares during the period. Main Street Financial Solutions LLC bought a new stake in shares of Abbott Laboratories in the 2nd quarter valued at about $1,194,000. Fidelity National Financial Inc. purchased a new stake in Abbott Laboratories during the 2nd quarter valued at about $20,235,000. Finally, Alpine Woods Capital Investors LLC grew its position in Abbott Laboratories by 1,199.3% during the 2nd quarter. Alpine Woods Capital Investors LLC now owns 43,202 shares of the healthcare product maker's stock worth $3,920,000 after acquiring an additional 39,877 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Stock Up 0.9%

Shares of Abbott Laboratories stock opened at $112.63 on Friday. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The company has a market cap of $194.89 billion, a P/E ratio of 36.45, a PEG ratio of 2.16 and a beta of 0.59. The company's fifty day simple moving average is $102.61 and its two-hundred day simple moving average is $100.22.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $12.59 billion during the quarter, compared to analysts' expectations of $12.52 billion. During the same period last year, the company posted $1.26 EPS. The company's quarterly revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were issued a dividend of $0.63 per share. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. Abbott Laboratories's dividend payout ratio is 81.55%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ABT. UBS Group cut their target price on shares of Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating on the stock in a report on Tuesday, July 28th. Bank of America dropped their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. The Goldman Sachs Group decreased their price objective on shares of Abbott Laboratories from $121.00 to $113.00 and set a "buy" rating on the stock in a research report on Wednesday, May 27th. Weiss Ratings raised shares of Abbott Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, August 6th. Finally, Piper Sandler reissued an "overweight" rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $119.50.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA approved Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients age two and older. The wearable is the first of its kind to track both glucose and ketones, strengthening Abbott’s position in diabetes care and creating potential for future integration with insulin-pump systems. FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
• Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is designed to reduce stroke risk in certain atrial-fibrillation patients and may reduce reliance on blood-thinning medication, supporting growth in Abbott’s structural-heart business. Abbott's next-generation Amulet 360 device receives CE Mark
• Positive Sentiment: Analyst coverage remains supportive, with TD Cowen expecting Abbott’s stock to rise. Separately, Zacks highlighted ABT as a strong long-term momentum candidate, suggesting improving price trends and investor interest despite its premium valuation. TD Cowen Analyst Says Abbott Stock Price Expected to Rise
• Neutral Sentiment: Abbott’s latest reported quarter exceeded consensus estimates, with earnings and revenue growing year over year. Management’s 2026 earnings guidance also points to continued expansion, but ABT’s elevated price-to-earnings ratio leaves the stock sensitive to execution and valuation concerns.
• Negative Sentiment: Recent coverage noted that Abbott shares fell 2.2% in the prior session even as the broader market advanced, reflecting near-term underperformance and possible profit-taking. The stock remains well below its 12-month high, so investors may want evidence that the new devices translate into meaningful sales growth. Abbott Stock Sinks as Market Gains

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source